SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs prolonged slide and perceived underperformance are driving bearish discussion, with traders citing broader crypto weakness and uncertainty over the Clarity Act after the midterms. Some blame Ripples token sales and question XRPs utility, while others view the decline as a buying opportunity and continue accumulating.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs quarterly results and raised full-year revenue outlook have driven a sharp rebound, with bullish traders pointing to strong growth, a larger backlog and customer demand. Others question how much growth came from the SkyWater acquisition and remain wary of cash burn, dilution and whether the rally can hold.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Debate over Snowflakes consumption-based model is driving attention, with traders warning that tighter budgets could lead customers to cut queries, storage and AI workloads, pressuring usage-linked revenue. Others see the models flexibility as a source of recovery when spending improves, while dip buyers and bearish traders remain divided on the stocks direction.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflares Q3 results beat expectations and its raised outlook drove a sharp rally, with traders highlighting accelerating growth and resilience amid a broader tech selloff. The reaction is divided between bulls welcoming the beat-and-raise and skeptics questioning the rich valuation and whether the post-earnings gains will hold.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

PANWs steep pullback ahead of its earnings report is driving discussion, with traders questioning whether AI spending is squeezing cybersecurity budgets and whether the stocks valuation leaves room for further downside. Others see the selloff as a buying opportunity, arguing that AI-related threats will sustain security demand.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp, volatile selloff is driving attention to Strategy as a leveraged BTC proxy, with traders debating whether the weakness could deepen the stocks losses. Bears also cite dilution, preferred-stock obligations and a possible MSCI removal as risks, while bulls argue the pullback is a buying opportunity and look for a rebound.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces decline is drawing debate over whether it can monetize AI add-ons at renewals when customers may be cutting employee seat counts and software budgets. Traders question whether Agentforce can generate paid demand beyond bundled offers, while others focus on nearby technical support levels.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius drew attention after reporting a better-than-expected third quarter, with Alani Nu and international growth offsetting a decline in the flagship Celsius brand. Traders welcomed the beat but debated whether Alani can sustain portfolio growth, while margin compression and core-brand weakness tempered optimism.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

UUUUs sharp, sustained selloff and underperformance versus uranium and rare-earth peers dominate discussion, with traders pointing to dilution risk and uncertainty around the VAC acquisition after the loss of a major customer supply agreement. Bulls argue the uranium and mine-to-magnet strategy remains a long-term opportunity, while skeptics question the deals cost, capital needs and execution risks.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

A wave of analyst downgrades and target cuts following UiPaths Investor Day has put pressure on the shares, with skeptics questioning whether agentic-AI products can drive faster growth and overcome customer concerns about adoption and pricing. Bulls argue the companys orchestration products and enterprise AI opportunity are undervalued, while others see the selloff as evidence that UiPath has yet to turn its AI pitch into stronger growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue Estimates

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +40.00% and +6.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Reports Third Quarter 2026 Financial Results

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates. Key Financial Results...

Maravai LifeSciences Announces November 2026 Investor Conference Schedule

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2026, at 10:40 a.m. EST, Raj Asarpota, Executive...

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter financial and operating results after the market close on Wednesday, November 4, 2026, and will host a conference...

Full Transcript: Maravai LifeSciences Q2 2026 Earnings Call

Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.
This transcript is brought to you byread more...

TriLink BioTechnologies Secures Additional China Patent for CleanCap Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

TriLink BioTechnologies, LLC (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has been granted a new patent from the China National Intellectual Property Administration (CNIPA), Patent number ZL202511246658.5...

Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?

Perrigo (PRGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial 

Equity

TEM stock rose as investors connected the upbeat clinical results to Tempus’s planned $1.5 billion acquisition of Personalis, announced last month.


Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates

Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +60.00% and +4.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates. Key Financial Results...

$MRVI Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.03 up 62.50% YoY
• Reported revenue of $45.85M up 10.14% YoY
• Maravai raised full-year 2026 revenue guidance to $212M to $216M from $205M to $215M, and Adjusted EBITDA guidance to $40M to $42M.

Stocktwits

Maravai LifeSciences Holdings Inc - Ordinary Shares - Class A

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.03 up 62.50% YoY
• Reported revenue of $45.85M up 10.14% YoY
• Maravai raised full-year 2026 revenue guidance to $212M to $216M from $205M to $215M, and Adjusted EBITDA guidance to $40M to $42M.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$0.03 up 62.50% YoY
• Reported revenue of $45.85M up 10.14% YoY
• Maravai raised full-year 2026 revenue guidance to $212M to $216M from $205M to $215M, and Adjusted EBITDA guidance to $40M to $42M.

Maravai reported a -$24M Q3 2026 net loss, cited uncertainty around high-volume CleanCap revenue, and identified larger competitors potential to make its products, services, and technology obsolete.

Maravais Q3 2026 revenue was $45.9M, with TriLink and Cygnus year-over-year growth; mRNA revenue rose 28%, four Discovery customers transitioned to clinical-stage GMP, and Adjusted EBITDA was $5.8M.

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Bullish Sentiment

<ul class="summary-bullets"><li>In a joint announcement earlier today, Merck and Moderna said their Phase 3 INTerpath-001 study met its main goal of keeping patients free from cancer longer after surgery.</li><li>BNTX, NVAX, MRVI, and RGEN are also rallying on the news.&nbsp;</li><li>Leerink said the unexpected Phase 3 success should support positive momentum for Merck into the fall while helping cancer-vaccine stocks overall, though any BioNTech gains may prove temporary.</li></ul><p>Shares of Tempus AI (TEM) climbed 22% on Wednesday after Merck and Moderna reported positive late-stage trial results for their personalized mRNA cancer treatment.</p><h2 class="st-heading-2">Why Tempus Is Rallying</h2><p>Investors are tying the favorable outcome directly to Tempus’s announced $1.5 billion purchase of Personalis from last month. Personalis furnishes the high-precision genomic sequencing that pinpoints each patient’s unique tumor mutations, which Moderna then uses to engineer the corresponding individualized mRNA dose.</p><p>Tempus already works with Personalis on cancer monitoring tests and will take ownership of the technology once the transaction closes. Observers are treating the late-stage trial success as preliminary validation that the platform functions effectively in a real late-stage clinical environment, thereby strengthening conviction in the strategic upside Tempus is poised to capture.</p><h2 class="st-heading-2">Merck-Moderna Trial Results</h2><p>In a joint announcement earlier today, Merck and Moderna said their Phase 3 INTerpath-001 study met its main goal of keeping patients free from cancer longer after surgery. It also met a key secondary goal of lowering the risk that the cancer would spread to distant parts of the body. The trial tested an individualized mRNA therapy called intismeran autogene, given with Merck’s Keytruda, against Keytruda alone.</p><p>It enrolled 1,137 patients with high-risk melanoma that had been completely removed by surgery and who had received no prior systemic treatment. At a planned interim look, the combination delivered statistically significant and clinically meaningful gains on both measures compared with Keytruda alone. No new safety concerns appeared. The companies plan to share full data at a future medical meeting and discuss possible approval filings with regulators.</p><h2 class="st-heading-2">Other Stocks To Rally On The News</h2><p>Related equities also advanced on the news. BioNTech and Novavax advanced as investors weighed broader implications for cancer vaccines. Maravai LifeSciences, a supplier of key ingredients for mRNA production, and Repligen, a maker of specialized bioprocessing tools, posted gains on the prospect that further progress with this class of cancer therapy could expand demand across manufacturing and supply-chain infrastructure.</p><p><a href="https://stocktwits.com/symbol/BNTX">BNTX</a> traded 20% higher at the time of writing, while <a href="https://stocktwits.com/symbol/MRVI">MRVI</a> and <a href="https://stocktwits.com/symbol/RGEN">RGEN</a> gained 25% and 6%, respectively. &nbsp;<a href="https://stocktwits.com/symbol/NVAX">NVAX</a> added 6%.</p><p>Analyst notes underscored the sector lift. Leerink said the unexpected Phase 3 success should support positive momentum for Merck into the fall while helping cancer-vaccine stocks overall, though any BioNTech gains may prove temporary.</p><p>Wells Fargo pointed to potential benefits for suppliers such as Repligen, Danaher, Thermo Fisher, and Maravai, noting that validation of the approach could encourage further investment. Stifel called the results good for Repligen, which has ties to the program, and conceptually positive for Maravai as vaccine work beyond COVID gains traction.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around TEM improved from extremely bearish to bullish territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ level.</p><p>According to data from Koyfin, eight of the 16 analysts covering TEM rate it ‘Buy’ or higher, while seven rate it ‘Hold’ and one ‘Sell.’ The 12-month average price target on the stock is $62.64, implying a potential upside of about 27% from the stock’s last close.</p><p><a href="https://stocktwits.com/symbol/TEM">TEM stock</a> has gained 2% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rare-stock-clocks-two-consecutive-days-of-losses-ahead-of-weekend-fda-decision-on-gene-therapy/cZYcqXORJjz">RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Tempus AI logo is seen displayed on a smartphone screen.

In a joint announcement earlier today, Merck and Moderna said their Phase 3 INTerpath-001 study met its main goal of keeping patients free from cancer longer after surgery.BNTX, NVAX, MRVI, and RGEN are also rallying on the news. Leerink said the unexpect

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial

BioNTech SE - ADR

Novavax Inc

Repligen Corp.

Tempus AI Inc

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.04	--	--	N/A
Q3 '26	-$0.06	-$0.03	46.73%	BEAT
Q2 '26	-$0.04	-$0.02	54.05%	BEAT
Q1 '26	-$0.04	$0.01	123.56%	BEAT
Q4 '25	-$0.07	-$0.04	43.06%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

MRVI Earnings

Latest Earnings Results: Q3 '26

Historical Earnings